Your Search Results

Everolimus-eluting stents or bypass surgery for mutivessel coronary artery disease: 10-year outcomes of multicenter randomized controlled BEST trial

20 Sep 2022

Nicola Ryan provides her take on the BEST trial which was presented by Jung-Min Ahn at TCT 2022.

It is a randomised, multicentre, non-inferiority trial comparing PCI with second-generation everolimus-eluting stents and CABG in patients with non-left main multivessel coronary artery disease. At two-year follow-up PCI was shown...

Author

Nicola Ryan

10-Year Outcomes of Multicenter Randomized Controlled BEST Trial: Everolimus-Eluting Stents or Bypass Surgery for Mutivessel CAD

The Lancet Commission to reduce global burden of cardiovascular disease in women by 2030

29 Aug 2021

Vijay Kunadian summarizes the key points of the LBT session of the ESC congress 2021 held on Sunday, 29 August focusing on the Lancet Commission to reduce the global burden of heart disease in women by 2030.

Author

Vijay Kunadian

ESC Congress 2021 - Global burden of cardiovascular disease in women; 20/20 vision for 2030: report of The Lancet commission

The AQUATIC trial: Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation

01 Sep 2025

Chiara De Biase provides her take on the results of AQUATIC presented by Martine Gilard at ESC Congress 2025 in Madrid.

Author

Chiara De Biase

The AQUATIC trial [Assessment of quitting versus using aspirin therapy in patients with stabilized coronary artery disease after stenting who require long-term oral anticoagulation: Rationale for and design of the AQUATIC double-blind randomized trial]

23 results for «107»

23 results